{"title":"第一代和第二代抗抑郁药用于治疗创伤性脑损伤引起的抑郁症的最新进展","authors":"Nicla Tranchida , Francesca Inferrera , Salvatore Cuzzocrea , Marika Cordaro , Rosanna Di Paola","doi":"10.1016/j.pnpbp.2025.111458","DOIUrl":null,"url":null,"abstract":"<div><div>One of the leading causes of disability leading to depression and other neuropsychiatric complications is traumatic brain injury, especially among young people. Post-TBI depression is a common condition with a significant impact on quality of life, recovery, and rehabilitation. In the last years, the second-generation antidepressants SNRIs and SSRIs have been applied as treatments for depression in patients with TBI. Due to the more favorable side effect profiles, these agents are considered over first-generation antidepressants. While further studies are needed to identify specific mechanisms and interactions with drug-induced brain trauma effects, preliminary studies do suggest that second-generation antidepressants may be useful in treating post-TBI depression. This review focus on the benefits, challenges, and emerging scientific evidence regarding the use second-generation antidepressants in TBI patients.</div></div>","PeriodicalId":54549,"journal":{"name":"Progress in Neuro-Psychopharmacology & Biological Psychiatry","volume":"141 ","pages":"Article 111458"},"PeriodicalIF":3.9000,"publicationDate":"2025-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Updates on first- and second-generation antidepressants used in the treatment of traumatic brain injury-induced depression\",\"authors\":\"Nicla Tranchida , Francesca Inferrera , Salvatore Cuzzocrea , Marika Cordaro , Rosanna Di Paola\",\"doi\":\"10.1016/j.pnpbp.2025.111458\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>One of the leading causes of disability leading to depression and other neuropsychiatric complications is traumatic brain injury, especially among young people. Post-TBI depression is a common condition with a significant impact on quality of life, recovery, and rehabilitation. In the last years, the second-generation antidepressants SNRIs and SSRIs have been applied as treatments for depression in patients with TBI. Due to the more favorable side effect profiles, these agents are considered over first-generation antidepressants. While further studies are needed to identify specific mechanisms and interactions with drug-induced brain trauma effects, preliminary studies do suggest that second-generation antidepressants may be useful in treating post-TBI depression. This review focus on the benefits, challenges, and emerging scientific evidence regarding the use second-generation antidepressants in TBI patients.</div></div>\",\"PeriodicalId\":54549,\"journal\":{\"name\":\"Progress in Neuro-Psychopharmacology & Biological Psychiatry\",\"volume\":\"141 \",\"pages\":\"Article 111458\"},\"PeriodicalIF\":3.9000,\"publicationDate\":\"2025-07-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Progress in Neuro-Psychopharmacology & Biological Psychiatry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S027858462500212X\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Progress in Neuro-Psychopharmacology & Biological Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S027858462500212X","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
Updates on first- and second-generation antidepressants used in the treatment of traumatic brain injury-induced depression
One of the leading causes of disability leading to depression and other neuropsychiatric complications is traumatic brain injury, especially among young people. Post-TBI depression is a common condition with a significant impact on quality of life, recovery, and rehabilitation. In the last years, the second-generation antidepressants SNRIs and SSRIs have been applied as treatments for depression in patients with TBI. Due to the more favorable side effect profiles, these agents are considered over first-generation antidepressants. While further studies are needed to identify specific mechanisms and interactions with drug-induced brain trauma effects, preliminary studies do suggest that second-generation antidepressants may be useful in treating post-TBI depression. This review focus on the benefits, challenges, and emerging scientific evidence regarding the use second-generation antidepressants in TBI patients.
期刊介绍:
Progress in Neuro-Psychopharmacology & Biological Psychiatry is an international and multidisciplinary journal which aims to ensure the rapid publication of authoritative reviews and research papers dealing with experimental and clinical aspects of neuro-psychopharmacology and biological psychiatry. Issues of the journal are regularly devoted wholly in or in part to a topical subject.
Progress in Neuro-Psychopharmacology & Biological Psychiatry does not publish work on the actions of biological extracts unless the pharmacological active molecular substrate and/or specific receptor binding properties of the extract compounds are elucidated.